Cyclin-dependent kinase 6 (CDK6) plays a crucial role in the G1 phase to S phase transition of the cell cycle. Aberrant activation of CDK6 has been linked with the development and progression of cancers such as leukemia, lymphoma and solid tumors. A recent study published in Bioorganic & Medicinal Chemistry aimed to discover novel proteolysis-targeting chimera (PROTAC) molecules as CDK6 inhibitors.